ClinVar Miner

Submissions for variant NM_018100.4(EFHC1):c.779G>A (p.Arg260Gln)

gnomAD frequency: 0.00008  dbSNP: rs145754721
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000766896 SCV000240931 uncertain significance not provided 2015-10-21 criteria provided, single submitter clinical testing p.Arg260Gln (CGG>CAG): c.779 G>A in exon 5 of the EFHC1 gene (NM_018100.3). The R260Q variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project. The R260Q variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. However, this substitution occurs at a position that is not highly conserved across species within the second DM10 domain of the protein and in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in CHILD-EPI panel(s).
Illumina Laboratory Services, Illumina RCV000378920 SCV000464164 uncertain significance Juvenile myoclonic epilepsy 2016-06-14 criteria provided, single submitter clinical testing
Athena Diagnostics RCV000187346 SCV000613249 likely benign not specified 2017-06-09 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV003765174 SCV001722081 benign Absence seizure; Myoclonic epilepsy, juvenile, susceptibility to, 1 2022-02-04 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000187346 SCV005380672 likely benign not specified 2024-08-12 criteria provided, single submitter clinical testing Variant summary: EFHC1 c.779G>A (p.Arg260Gln) results in a conservative amino acid change located in the DM10 domain (IPR006602) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00041 in 1613938 control chromosomes, predominantly at a frequency of 0.0018 within the South Asian subpopulation in the gnomAD database, including 4 homozygotes (gnomAD v4.1.0). c.779G>A has been reported in the literature in at least an individual affected with Juvenile Myoclonic Epilepsy (example: Thounaojam_2017). These report(s) do not provide unequivocal conclusions about association of the variant with Juvenile Myoclonic Epilepsy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 34426522, 29750216). ClinVar contains an entry for this variant (Variation ID: 205389). Based on the evidence outlined above, the variant was classified as likely benign.
PreventionGenetics, part of Exact Sciences RCV003907654 SCV004727238 likely benign EFHC1-related disorder 2020-10-28 no assertion criteria provided clinical testing This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.